ArticlePLoS neglected tropical diseases2015
Development and validation of a luminescence-based, medium-throughput assay for drug screening in Schistosoma mansoni.
Article in PLoS neglected tropical diseases, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 49 citations in OpenAlex.
- Benzodeazaoxaflavin Sirtuin Inhibitors InhibitACS infectious diseases · 2025Article
- Effects of structurally distinct human HDAC6 and HDAC6/HDAC8 inhibitors against S. mansoni larval and adult worm stages.PLoS neglected tropical diseases · 2024Article
- Non-covalent inhibitors of thioredoxin glutathione reductase with schistosomicidal activity in vivo.Nature communications · 2023Article
- Optimizing the xWORM assay for monitoring hookworm larvae motility.Frontiers in parasitology · 2023Article
- A self-purifying microfluidic system for identifying drugs acting against adult schistosomes.Royal Society open science · 2022Article
- Comparative metabolic profiling byParasitology research · 2022Article
- Traditional Kenyan herbal medicine: exploring natural products' therapeutics against schistosomiasis.Journal of helminthology · 2022Article
- Natural-Product-Based Solutions for Tropical Infectious Diseases.Clinical microbiology reviews · 2021Review
- A lack of ChREBP inhibits mitochondrial cristae formation in brown adipose tissue.Molecular and cellular biochemistry · 2021Article
- The ATP bioluminescence assay: a new application and optimization for viability testing in the parasitic nematode Haemonchus contortus.Veterinary research · 2021Article
- High-content approaches to anthelmintic drug screening.Trends in parasitology · 2021Review
- Identification of hit compounds with anti-schistosomal activity on in vitro generated juvenile worms in cell-free medium.PLoS neglected tropical diseases · 2021Article
- Schistosomiasis Drug Discovery in the Era of Automation and Artificial Intelligence.Frontiers in immunology · 2021Review
- Drug effects on metabolic profiles of Schistosoma mansoni adult male parasites detected by 1H-NMR spectroscopy.PLoS neglected tropical diseases · 2020Article
- Parallelized Impedance-Based Platform for Continuous Dose-Response Characterization of Antischistosomal Drugs.Advanced biosystems · 2020Article
- Investigating the Antiparasitic Potential of the Marine Sesquiterpene Avarone, Its Reduced form Avarol, and the Novel Semisynthetic Thiazinoquinone Analogue Thiazoavarone.Marine drugs · 2020Article
- Multi-center screening of the Pathogen Box collection for schistosomiasis drug discovery.Parasites & vectors · 2019Article
- Article
- Chemical Investigation of the Indonesian TunicateMarine drugs · 2019Article
- Life cycle maintenance and drug-sensitivity assays for early drug discovery in Schistosoma mansoni.Nature protocols · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSchistosomiasis, one of the world's greatest neglected tropical diseases, is responsible for over 280,000 human deaths per annum. Praziquantel, developed in the 1970s, has high efficacy, excellent tolerability, few and transient side effects, simple administration procedures and competitive cost and it is currently the only recommended drug for treatment of human schistosomiasis. The use of a single drug to treat a population of over 200 million infected people appears particularly alarming when considering the threat of drug resistance. Quantitative, objective and validated methods for the screening of compound collections are needed for the discovery of novel anti-schistosomal drugs. METHODOLOGY/PRINCIPAL
findingsThe present work describes the development and validation of a luminescence-based, medium-throughput assay for the detection of schistosomula viability through quantitation of ATP, a good indicator of metabolically active cells in culture. This validated method is demonstrated to be fast, highly reliable, sensitive and automation-friendly. The optimized assay was used for the screening of a small compound library on S. mansoni schistosomula, showing that the proposed method is suitable for a medium-throughput semi-automated screening. Interestingly, the pilot screening identified hits previously reported to have some anti-parasitic activity, further supporting the validity of this assay for anthelminthic drug discovery.
conclusionsThe developed and validated schistosomula viability luminescence-based assay was shown to be successful and suitable for the identification of novel compounds potentially exploitable in future schistosomiasis therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.